Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, open label, uncontrolled, non-comparative phase I/II study in
patients with refractory or relapsed multiple myeloma who are eligible for second, third, or
fourth line therapy. Patients will be enrolled sequentially into four dose cohorts. The
feasibility of administrating Revlimid (R) in combination with Doxorubicin and Dexamethasone
(AD) and the MTD of the combination will be determined in the phase I part of the study (Part
A). When the MTD has been established, the efficacy of the combination will be further
evaluated in the phase II part of the study Part B)